[MELANOMA INCIDENCE, IMMIGRATION AND ORIGIN].

Harefuah

Plastic and Reconstructive Surgery Department, Rambam Health Care Campus, Haifa, Israel.

Published: August 2020

Background: Melanoma is a malignant tumor of melanocytes, whose prevalence has been increasing in recent decades. Early diagnosis allows removal of the tumor prior to the metastatic stage and may lead to a complete recovery.

Objectives: To compare melanoma incidence among different epidemiological groups in northern Israel, and to assess the impact of migration on the increase in incidence of the disease.

Methods: A retrospective review was conducted of the medical records of all patients diagnosed with melanoma and treated in the Plastic Surgery Department at the Rambam Health Care Campus in 2016. Demographic data of 130 patients and tumor characteristics were collected and analyzed.

Results: European and American immigrants were found to carry an increased risk for melanoma compared to African and Asian immigrants. Increased melanoma risk was also found among a large subset of European immigrants from the former Soviet Union. This sub-group accounted for 32% of study group patients, while they only comprise 9% of the population (p <0.05). Most melanoma tumors in this sub-group were found in upper and lower extremities (60%). Disease was diagnosed at a younger age compared to the other European immigrants (p <0.05), with a trend towards a more advanced disease than the rest of the patients.

Conclusions: Study findings imply an increased melanoma risk in immigrants from the former Soviet Union. Raising awareness of this population to preventative measures and the importance of early diagnosis may reduce morbidity and mortality caused by the disease. Further research is needed to determine whether routine screening tests should be applied to this population.

Download full-text PDF

Source

Publication Analysis

Top Keywords

melanoma
5
[melanoma incidence
4
incidence immigration
4
immigration origin]
4
origin] background
4
background melanoma
4
melanoma malignant
4
malignant tumor
4
tumor melanocytes
4
melanocytes prevalence
4

Similar Publications

Immune checkpoint inhibitors (ICIs) have advanced the treatment of metastatic melanoma. However, some patients develop ICI-associated toxicities like hepatitis (ie, immune-mediated hepatitis; IMH). Although these toxicities usually resolve with steroids, steroid-refractory events may occur, which may be a major source of morbidity and mortality without obviously defined treatment algorithms.

View Article and Find Full Text PDF

Melanoma is an aggressive type of skin cancer that arises from melanocytes, the cells responsible for producing skin pigment. In contrast to non-melanoma skin cancers like basal cell carcinoma and squamous cell carcinoma, melanoma is more invasive. Melanoma was distinguished by its rapid progression, high metastatic potential, and significant resistance to conventional therapies.

View Article and Find Full Text PDF

Melanoma brain metastasis (MBM) is linked to dismal prognosis, low overall survival, and is detected in up to 80% of patients at autopsy. Circulating tumor cells (CTCs) are the smallest functional units of cancer and precursors of fatal metastasis. We previously employed an unbiased multilevel approach to discover a unique ribosomal protein large/small subunits (RPL/RPS) CTC gene signature associated with MBM.

View Article and Find Full Text PDF

Neurologic immune-related adverse events (nirAEs) represent rare, yet severe side effects associated with immune checkpoint inhibitor (ICI) therapy. Given the absence of established diagnostic biomarkers for nirAEs, we aimed to evaluate the diagnostic utility of serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP). Fifty-three patients were included at three comprehensive cancer centers, of these 20 patients with manifest nirAEs and 11 patients with irHypophysitis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!